221 filings
6-K
MESO
Mesoblast Ltd
24 Dec 19
Mesoblast’s Phase 3 Trial of Revascor In Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion
12:00am
6-K
MESO
Mesoblast Ltd
12 Dec 19
Current report (foreign)
12:00am
6-K
MESO
Mesoblast Ltd
29 Nov 19
Current report (foreign)
6:47am
6-K
MESO
Mesoblast Ltd
27 Nov 19
Current report (foreign)
6:04am
6-K
MESO
Mesoblast Ltd
27 Nov 19
Continued Increase in Revenues and Strong Balance Sheet
6:04am
6-K
vfrrp
7 Nov 19
Mesoblast Quarterly Cash Flow Report
12:00am
6-K
q8jexkkezbjgx2ve
1 Nov 19
Appointment of Joint Company Secretary
6:02am
6-K
fj9gw vu3
21 Oct 19
Mesoblast and Lonza Enter into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy
8:19pm
6-K
if2rl2
10 Oct 19
Current report (foreign)
6:04am
6-K
3rsqq
4 Oct 19
Mesoblast Completes Successful Institutional Capital Raising of A$ 75 Million
6:04am
6-K
02xayezgaf cri4eg
3 Oct 19
Current report (foreign)
6:03am
6-K
789yn
11 Sep 19
Current report (foreign)
6:35am
6-K
y6p4p6b 86j2fce4p
6 Sep 19
Mesoblast Reports 2019 Full Year Results
6:35am
6-K
d5h1injy8 k8qontmc
30 Aug 19
Current report (foreign)
6:01am
6-K
5vymbc6j1f8k h07soy8
19 Aug 19
Remestemcel-l to Be Evaluated As Treatment for Chronic Graft Versus Host Disease In Planned Investigator-initiated Trial
6:04am
6-K
ihhpvp0
12 Aug 19
Mesoblast Appoints Leading Pharmaceutical Industry Executive As Chief Medical Officer
9:21pm
6-K
z4yc9b
2 Aug 19
Mesoblast Quarterly Cash Flow Report
12:00am
6-K
upep9ilom8j40u
30 Jul 19
Circulation Research Special Article Highlights Potential of
12:00am
6-K
mdrxc w5glnq3l6
16 Jul 19
New Issue Announcement
8:35pm